Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash & Equivalents (2024 - 2025)

Xilio Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $103.8 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 69.39% year-over-year to $103.8 million; the TTM value through Sep 2025 reached $103.8 million, up 69.39%, while the annual FY2024 figure was $55.3 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2025 was $103.8 million at Xilio Therapeutics, down from $121.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $121.6 million in Q2 2025 and bottomed at $34.0 million in Q1 2024.